Clinical Trials for MG 2020

Myasthenia Gravis Association

Study	Study Sponsor Details	Location(s)	Physician	Study Coordinator Contact
Safety & Efficacy Study of Ravulizumab in Adults with Generalized Myasthenia Gravis	Alexion Pharmaceuticals: ALXN1210-MG-306	University of Kansas City Medical Center	Dr. Mazen Damachkie	Katie Jennens
		Washington University School of Medicine	Dr. Muhammad Al-Lozi	June Smith smith.june@wustl.edu

Snapshot

The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG). All investigative site personnel, sponsor staff, sponsor designees, staff directly associated with the conduct of the study, and all participants will be blinded to treatment assignments. This is a randomized, control trial in which the patient will receive either the investigational drug or placebo drug through an IV infusion. After the 26-week randomized-controlled period, participants will enter the open-label extension period of the study and receive ravulizumab. If interested in this study, please contact the appropriate study coordinator based on location and physician of interest.

Other Helpful Information

Study Website: https://mgchampion.com/
Clinical Trials Website: https://clinicaltrials.gov/ct/2/show/NCT03920293

Study	Study Sponsor Details	Location(s)	Physicians	Study Coordinator Contact
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients with Generalized Myasthenia Gravis	UCB Biopharma S.P.R.L.: UCB MG0003	University of Kansas City Medical Center	Dr. Mazen Damachkie	Ali Ciersdorff
		Washington University School of Medicine	Dr. Muhammad Al-Lozi	June Smith smith.june@wustl.edu

Snapshot

The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (gMG). This is a randomized, control trial in which the patient will receive either the investigational drug or placebo through subcutaneous infusion. If interested in this study, please contact the appropriate study coordinator based on location and physician of interest.

Other Helpful Information

Study Website: https://www.mycaringstudy.com/
Clinical Trials Website: https://clinicaltrials.gov/ct2/show/NCT03971422

Study	Study Sponsor Details	Location(s)	Physicians	Study Coordinator Contact
A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants with Refractory Generalized Myasthenia Gravis (gMG)	Alexion Pharmaceuticals: ECU-MG-303	Saint Louis University	Dr. Jafar Kafaie	Jennifer Light Jennifer.light@health.slu.edu

Snapshot

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in the treatment of pediatric refractory gMG based on change from Baseline in the Quantitative Myasthenia Gravis (QMG) score for disease severity. The study will consist of an up to 4-week Screening Period, 26-week Primary Evaluation Treatment Period, an additional (up to) to 208-week Extension Period, and an 8-week Safety Follow-up Period. Eculizumab will be administered through an intravenous (IV) infusion. If interested in this study, please contact the appropriate study coordinator based on location and physician.

Other Helpful Information

Clinical Trials Website: https://clinicaltrials.gov/ct2/show/study/NCT03759366
Alexion Pharmaceuticals Contact: clinicaltrials@alexion.com

Study	Study Sponsor Details	Location(s)	Physicians	Study Coordinator Contact
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis	Ra Pharmaceuticals: RA101495-02.301	University of Kansas Medical Center	Dr. Constantine Farmakidis	Samantha Colgan

Snapshot

The RAISE study is a multicenter, randomized, double-blind, placebo-controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized myasthenia gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks. If interested in this study, please contact the appropriate study coordinator based on location and physician.

Other Helpful Information

Clinical Trials Website: https://clinicaltrials.gov/ct2/show/record/NCT04115293
Ra Pharmaceuticals Contact Info: trials@rapharma.com